Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Unichem

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links